Navigation Links
Boosting Pharma Sales Force Effectiveness through Streamlined Internal Communications
Date:12/12/2007

CHAPEL HILL, N.C., Dec. 12 /PRNewswire/ -- The success of a pharmaceutical sales force is built on effective communication. Yet ineffective internal communication between sales reps and regional corporate sources are eating into reps' time on the job, according to a new study by benchmarking leader Best Practices, LLC.

Pharma sales reps spend an average of 13.7 hours a week managing internal communication and, of that, 4.4 hours (or 32 percent) are perceived as unnecessary, according to the study. Most of those 4.4 hours is made up of email and cell phone communications and a vast majority of the communications comes from regional and local sources, according to the study. Sales reps estimate they receive more than 150 email and voicemail communications a week from regional sources.

Pharmaceutical companies could increase sales staff productivity by more than 10 percent by eliminating unnecessary internal communications to the field, according to the study. To learn more about this report, Pharma Sales Force Effectiveness: Increasing Productivity Through Streamlined Internal Communication, please download a complimentary report excerpt and study overview at http://www3.best-in-class.com/rr890.htm

The research is based on interviews and benchmarking surveys from 10 leading pharmaceutical and biotech companies, including Pfizer, Eli Lilly, Genentech, Johnson & Johnson and Merck. Executives and managers who oversee sales operations can use this study to improve the productivity of their field sales force.

The research findings from this study highlight significant costs of unnecessary communication across a direct sales force as well as the best practices that sales communications functions, district managers, sales reps and IT managers can use to help prevent unnecessary internal communication.

Some of the key topics covered in the report include:

-- Total time spent on internal communication

-- Percentage of unnecessary time spent

-- Costs of unnecessary communication

-- Most effective communication methods

To learn more about this report, including key findings and sample best practices, download a complimentary excerpt at: http://www3.best-in- class.com/rr890.htm .

For questions or additional information on Best Practices, LLC's other products and services, please call Cameron Tew at 919-767-9246 or email ctew@best-in-class.com. Also, visit our Web site at: http://www.best-in-class.com/.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a research and consulting firm that conducts work based on the principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more information, call 919-403-0251 or visit http://www3.best-in-class.com/.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. Schools Getting Better at Boosting Kids Health
2. Mayo Clinic researchers: Insulin-boosting medication does not impair ability to survive heart attack
3. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
4. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
10. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
11. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
Breaking Medicine Technology: